Business
Servier acquires Edgewise's muscular dystrophy business for USD 2.65 billion, gaining sevasemten rights
France-based Servier has completed its acquisition of the muscular dystrophy business of Boulder, Colorado-based Edgewise Therapeutics (Nasdaq: EWTX) for up...
Apnimed files for Nasdaq IPO with NDA-stage sleep apnea therapy under FDA review
Cambridge, Massachusetts-based Apnimed, Inc. (Nasdaq: APMD) filed for an IPO on July 10, 2026, seeking a Nasdaq listing for a company whose sole clinical...
Zhaoke flips regional license into global ownership of late-stage myopia drop NVK002
Zhaoke Ophthalmology converts regional licensee status into global IP ownership of a late-stage myopia drop, leaving originator Nevakar with only a...
Ocugen expands OCU400 gene therapy footprint with MENA licensing deal ahead of Phase III readout
Ocugen (Nasdaq: OCGN) has signed a binding term sheet to license OCU400, its Phase III modifier gene therapy for retinitis pigmentosa, to Kuwait-based Roots...
Antengene pockets USD 60m from UCB as it pivots to monetizing proprietary TCE platform
Antengene Corporation Limited (HKEX: 6996) has confirmed receipt of the USD 60 million upfront payment from UCB under their worldwide exclusive license...
Tarsus bets USD 565 million to displace Betadine in intravitreal injection prep
Irvine, California-based Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) has acquired iRenix Medical, Inc., a privately held clinical-stage ophthalmic...
Cue Bio secures USD 50m to advance autoimmune pipeline after three-fold valuation jump
Boston-based Cue Biopharma, Inc. (Nasdaq: CUE) announced a USD 50 million private placement to fund clinical development across its immunological disorders...
Bayer raises EUR 3.0 billion by selling minority stake in contraceptives unit
Bayer (ETR: BAYN) has secured €3.0 billion in equity capital from Apollo Global Management (NYSE: APO) through a minority stake in a newly established...
MindRank's USD 52m Series B advances AI-designed GLP-1 into pivotal Phase III obesity trial
China-based MindRank AI Ltd. has closed a USD 52 million Series B financing round to advance its AI-native drug discovery platform and clinical pipeline,...
Apertura partners with NIH on TfR1 capsid approach for Niemann-Pick gene therapy
New York-based Apertura Gene Therapy has entered a Cooperative Research and Development Agreement with two NIH institutes to advance preclinical...
Teva secures ocrelizumab biosimilar rights across US and EU ahead of subcutaneous shift
Teva and Polpharma Biologics strike ocrelizumab biosimilar deal covering US, EU, and key global markets
Alchemab backed by British Business Bank with record USD 34 million life sciences bet
UK-based Alchemab Therapeutics has announced a £25 million (USD 34 million) extension to its Series A financing, with the capital provided solely by the...
Novo Nordisk agrees to evaluate Vivani's semaglutide implant ahead of Phase I trial
Novo Nordisk agrees to evaluate Vivani's semaglutide implant ahead of Phase I trial
GSK terminates USD 2.2 billion Alector collaboration after back-to-back clinical failures in dementia
GSK terminates Alector collaboration after back-to-back clinical failures in progranulin biology, ending a deal worth up to USD 2.2 billion and leaving the...
Tanabe Pharma exits manufacturing with plant sale to reshape as pure R&D player
Japan-based Towa Pharmaceutical Co., Ltd. (TSE: 4553) has agreed to acquire Tanabe Pharma Factory Co., Ltd., the manufacturing subsidiary of Tanabe Pharma...
The AllSci Brief
Systematic R&D and deal news. Daily.